Rapamycin markedly reduced VEGF-induced HUVEC proliferation in vitro, in a dose-dependent manner [126], suggesting targeting mTORC1 constrains tumor progression not only by acting on cancer cells, but also through an anti-angiogenic activity. Here, VEGFA is linked to cancer.